[Cancer immunotherapy. A future therapeutical choice?]

Area of Science:

• Oncology
• Immunology

Background:

• The concept of immune response to cancer has existed for decades.
• Cancer immunotherapy, despite its long history, is not always the primary treatment choice due to challenges like tumor-host antigenic similarity and reduced tumor immunogenicity.
• Various immunotherapy types exist, including aspecific, adoptive, specific active, and passive approaches.

Purpose of the Study:

• To review the historical context and evolution of cancer immunotherapy.
• To discuss the intrinsic difficulties and different modalities of cancer immunotherapy.
• To highlight the recent advancements and future potential of immunotherapy in cancer treatment.

Main Methods:

• Review of historical data and scientific literature on cancer immunotherapy.
• Categorization of different immunotherapy types (aspecific, adoptive, specific active, passive).
• Analysis of challenges and progress in developing and applying cancer immunotherapies.

Main Results:

• Immunotherapy has faced significant hurdles, including tumor cell characteristics that evade immune detection.
• Different immunotherapy strategies have been developed, including those using monoclonal antibodies, vaccines, and cell-based therapies.
• Substantial progress has been made in the 21st century, with ongoing research aiming to improve treatment efficacy.

Conclusions:

• Cancer immunotherapy has evolved significantly, overcoming historical limitations.
• Despite challenges, advancements in understanding tumor antigens and immune interactions are driving progress.
• Immunotherapy is increasingly recognized as a vital therapeutic strategy with a promising future in oncology.